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This manuscript is part of a commissioned series of urgent clinical guidance 
documents on the management of endocrine conditions in the time of COVID-19.  
This clinical guidance document underwent expedited open peer review by Jérôme 
Bertherat (Paris, France), André Lacroix (Montreal, Canada), Alberto Pereira (Leiden, 
The Netherlands), and Peter Trainer (Manchester, UK) 
 
Disclaimer: Due to the emerging nature of the COVID-19 crisis this document is not 
based on extensive systematic review or meta-analysis, but on rapid expert 
consensus. The document should be considered as guidance only; it is not intended 
to determine an absolute standard of medical care. Healthcare staff need to consider 
individual circumstances when devising the management plan for a specific patient. 
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Abstract 
 
Principles of care: Clinical evaluation should guide those needing immediate 
investigation. Strict adherence to COVID-19 protection measures is necessary. 
Alternative ways of consultations (telephone, video) should be used. Early discussion 
with regional/national experts about investigation and management of potential and 
existing patients is strongly encouraged.  
Patients with moderate or severe clinical features need urgent investigation and 
management. Patients with active CushiQJ¶VV\QGURPHHVSHFLDOO\ZKHQVHYHUHDUH
immunocompromised and vigorous adherence to the principles of social isolation is 
recommended. In patients with mild features or in whom a diagnosis is less likely,  
clinical re-evaluation should be repeated at three and six months or deferred until the 
prevalence of SARS-CoV-2 has significantly decreased; however, those individuals 
should be encouraged to maintain social distancing. Diagnostic pathways may need 
to be very different from usual recommendations in order to reduce possible exposure 
to SARS-CoV-2. When extensive differential diagnostic testing and/or surgery is not 
feasible, it should be deferred, and medical treatment should be initiated. 
Transsphenoidal pituitary surgery should be delayed during high SARS-CoV-2 viral 
prevalence. Medical management rather than surgery will be the used for most 
patients since the short- to mid-term prognosis depends in most cases on 
hypercortisolism rather than its cause; it should be initiated promptly to minimize the 
risk of infection in these immunosuppressed patients. 
The risk/benefit ratio of these recommendations will need re-evaluation every 2-3 
months from April 2020 in each country (and possibly local areas) and will depend on 
the local health care structure and phase of pandemic. 
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³,OPHJlLRHO¶LQLPicRGHOEHQH´RU³SHUIHFWLRQLVWKHHQHP\RIWKH
JRRG´ 
Voltaire, Dictionnaire Philosophique, 1770. 
 
 
Introduction 
 
The COVID-19 pandemic declared by the WHO in March 2020 requires 
endocrinologists to adapt to practices that do not sit easily with our norm of using 
detailed investigation and monitoring to achieve perfection. This is particularly the 
FDVHIRU&XVKLQJ¶VV\QGURPHZKHUHPDQDJHPHQWLVFRPSOH[DQGFKDOOHQJLQJHYHQ
in the best of times. Here we focus on key areas of the patient pathway to give practical 
advice for clinical practice, and highlight where these differ from usual 
recommendations and guidelines. 
 
Principles of care 
x Minimise outpatient attendance at time of high SARS-CoV-2 virus prevalence 
to reduce risks of COVID-19 illness for patients and hospital staff. 
Telephone/video clinics should be used as the preferred option for the vast 
majority of patients. 
x Patients with DFWLYH&XVKLQJ¶VV\QGURPHDUHimmunosuppressed and at risk of 
viral and other infections and should be advised to follow their government¶V 
guidance on social distancing and self-isolation/shielding, including taking sick 
leave; rapid normalization of cortisol secretion is needed to minimize the risk of 
infection.   
x Since diabetes mellitus and hypertension appear to be significant risk factors 
for adverse outcomes from COVID-19, these co-morbidities should be very 
actively managed. 
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x Minimise imaging requests at time of high COVID-19 virus prevalence to reduce 
risks to patients and hospital staff, and emergency pressure on the radiology 
service.  
x Surveillance imaging and laboratory investigations in otherwise stable patients 
should be deferred at time of high SAR-CoV-2 virus prevalence, and greater 
reliance placed on clinical assessment. 
x Good communication with patients is essential to explain the potential trade-
offs that will result from instituting this guidance with respect to survival, quality 
of life and functional outcomes, and the risk of acquiring COVID-19 and the 
resulting sequelae.  
x Discuss suspected/known &XVKLQJ¶V V\QGURPH patients with recognised 
experts in &XVKLQJ¶VV\QGURPHLQyour country to facilitate management. This 
is especially true where access to diagnostic and therapeutic resources is 
limited. 
x The risk/benefit ratio of these recommendations will need re-evaluation every 
2-3 months from April 2020 in each country (and possibly local areas) and will 
depend on the local health care structure and phase of pandemic, and how 
health care providers are able to structure care for patients with and without 
COVID-19, with a gradual return to more standard care. 
 
 
Diagnosis 
Clinical features: At the best of times, GLDJQRVLVDQGGLIIHUHQWLDOGLDJQRVLVRI&XVKLQJ¶V
syndrome may be challenging. During the COVID-19 pandemic the following 
principles should be applied: 
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x Attention must be given to the key clinical features that are more discriminating 
IRU&XVKLQJ¶VV\QGURPe1, so as to investigate those for whom the diagnosis is 
more likely and to avoid or defer investigation where the diagnosis is less likely. 
x If clinical features are mild, or in doubt, investigation should be deferred for 
three to six months after a repeat clinical assessment, and/or until SARS-CoV-
2 viral prevalence has significantly diminished.  This is justified on the basis that 
the benefits of treating WKHFDXVHRI&XVKLQJ¶VV\QGURPHLQSDWLHQWVwith mild 
disease is not fully established2. 
x Judgement of severity may need to be made by telephone, with assessment of 
the rapidity of symptom onset; video consultation may allow assessment of 
physical features. 
x When diagnostic testing is deferred, treatment of potential co-morbidities (such 
as hypertension and diabetes) should be optimized. 
x Those with moderate and severe clinical disease must be investigated and 
managed urgently since these patients are prone to develop various co-
morbidities requiring hospitalization and/or have immunosuppression that may 
potentially facilitate viral or other infections. 
x To facilitate triage, when referring patients to centres, the details of co-
morbidities (BP, glucose, etc.) as well as any known relevant biochemistry (e.g. 
serum cortisol) should be included. 
x Patients with adrenal incidentaloma should only be investigated for 
hypercortisolism at times of high SARS-CoV-2 viral prevalence if radiological 
features suggest adrenocortical cancer or clinical signs suggest moderate to 
severe &XVKLQJ¶VV\QGURPH3.  
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Biochemical investigations: 
The following principles are suggested: 
x Overnight dexamethasone suppression testing and 24-hour urinary free cortisol 
are recommended as first line tests, with measurement of serum electrolytes 
and glucose, complete blood count, CRP, HbA1c. 
x A basal plasma sample for ACTH should be measured at the beginning of the 
investigation process to allow rapid stratification into ACTH-dependent and 
independent disease, together with basal anterior pituitary function and 
androgens. 
x Salivary cortisol/cortisone tests should be avoided due to the potential for viral 
contamination and infection of laboratory staff, until it is known how long the 
virus remains infectious in salivary samples. 
x In the context of severe clinical signs RI&XVKLQJ¶VV\QGURPH and in the absence 
of major stressors (e.g. sepsis) a single measurement of serum cortisol may be 
sufficient to confirm the diagnosis if very elevated - e.g. >1000 nmol/L 
(37ug/dL), especially in the presence of an elevated neutrophil count and 
hypokalaemia4.  It is important to remember that oral oestrogens may cause 
higher measured serum cortisol due to increased CBG. Similarly, a single UFC 
![8/1LVKLJKO\VXJJHVWLYHRI&XVKLQJ¶VV\QGURPH 
  
 
Differential diagnosis. 
The usual detailed strategies for investigation RI WKHFDXVHRI&XVKLQJ¶VV\QGURPH 
have to be modified significantly during the COVID-19 pandemic. The following 
recommendations depart significantly from standard guidelines (Figure 1):   
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x 2QFH&XVKLQJ¶VV\QGURPHLVFRQILUPHG or highly likely, patients should undergo 
an immediate CT scan of thorax (with 1mm slice thickness), abdomen and 
pelvis (with 2-5 mm slice thickness) to identify adrenocortical cancer and overt 
disease causing the ectopic ACTH syndrome.  CT will immediately identify 
significant disease that may need urgent cancer surgery (e.g. adrenal cancer) 
or other investigation and management such as for small cell lung cancer. Also, 
it allows identification of major co-morbidities (vertebral fractures, infectious 
foci, pulmonary thromboembolism and atherosclerosis), which may guide 
further clinical care. 
x &XVKLQJ¶V disease is the PRVWIUHTXHQWDHWLRORJ\RI&XVKLQJ¶VV\QGURPHand 
the combination of clinical factors including reproductive age, female sex, slow 
onset of symptoms over several years, moderate increase in UFC (<4x ULN) 
and ACTH (plasma <100 pg/mL) have a high predictive value RI &XVKLQJ¶V
disease.  
x If there is visual field compromise on clinical examination and or severe 
headaches, pituitary imaging by MRI or CT should be performed. It should be 
noted, however, that a corticotroph macroadenoma is an unusual cause of 
PRGHUDWHVHYHUH&XVKLQJ¶VV\QGURPH 
x If there is no visual compromise it is reasonable to not perform a pituitary MRI, 
as in most cases oQFH WKH GLDJQRVLV RI &XVKLQJ¶V V\QGURPH LV FRQILUPHG, 
management should be with medical treatment, for at least three to six months, 
and whilst the prevalence of SARS-CoV-2 remains high. Furthermore, the 
confined nature of MRI scanners represents a potential transmission vector, 
especially in localities where patients with COVID-19 are being treated. 
Nevertheless, these suggestions may need modifying to more normal 
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standards of care depending on the state of the local health care system and 
pandemic at that location. 
x All other investigations should usually be avoided at the time of high SARS-
CoV-2 viral prevalence as they will not result in specific management because: 
o Transsphenoidal pituitary surgery should be avoided: this procedure 
results in aerosol formation which conveys a very high risk of viral 
transmission 5; it remains an option in urgent patients (or for other 
patients in the chronic phase of the pandemic) after negative SARS-
CoV-2 testing if hospital resources are available for safe care and the 
operation will be performed by a highly experienced pituitary surgeon. 
o Other testing including peripheral CRH or desmopressin testing, or 
bilateral petrosal sinus sampling can be deferred until SARS-CoV-2 
prevalence has decreased. 
o Once COVID-19 prevalence has decreased in a given society/locality, 
consideration can be given to stopping the medical treatment and 
initiating additional investigation of the aetiology once the patient is again 
hypercortisolaemic. Such an approach is justified on the basis of the key 
principles of care above, and the fact that some centres already routinely 
consider medical pre-treatment ahead of surgery2.  In addition, other 
than causes that specifically affect prognosis (ACC, pituitary 
macroadenomas, overtly resectable ectopic ACTH-secreting tumours), 
the short- to mid-WHUPSURJQRVLVRI&XVKLQJ¶VV\QGURPHLVUHODWHGWRWKH
cortisol excess and not its cause. 
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Treatment 
Overview: 
During high SARS-CoV-2 viral prevalence, surgery IRU&XVKLQJ¶VV\QGURPHVKRXOG be 
avoided or altered in most health care settings because: 
x The risks to patients of contracting COVID-19, and increasing immune 
suppression from major surgical intervention, and the potential risk to health 
care workers (e.g. transsphenoidal surgery as above).   
x If benefits of transsphenoidal surgery outweigh the risks (e.g. very active 
disease, difficult to control hypercortisolism despite steroidogenesis inhibitors, 
side effects of medical treatment), surgery should be done using appropriate 
protection (face masks with the highest level of protection for medical 
procedures ± e.g. FFP3 masks) after repeat negative testing for COVID-19, and 
only by a highly experienced pituitary surgeon.  
x When VXUJLFDOLQWHUYHQWLRQIRU&XVKLQJ¶s disease is needed because of visual 
compromise due to optic chiasm compression by a pituitary macroadenoma, 
consideration may also be given to DOLPLWHGµH\HEURZ¶FUDQLRWRP\to avoid the 
formation of aerosol droplets that occurs during transsphenoidal surgery (see 
above5). 
x Surgery can be deferred in the context of an imaging lesion highly suggestive 
of well-differentiated neuroendocrine tumour as an ectopic source of ACTH (e.g 
a pancreatic or lung lesion), if delay for up to around 3-6 months is unlikely to 
reduce life expectancy. The mainstay of treatment for patients is medical 
therapy to control hypercortisolaemia and its effects.  If there is delay to surgery, 
empirical use of somatostatin analogue therapy (in addition to steroidogenesis 
inhibitors) can be considered for their anti-tumour effects in patients with 
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tumours that are, or are highly likely to, be well-differentiated neuroendocrine 
tumours, even without performing somatostatin receptor imaging. 
x $Q\SDWLHQWVGLDJQRVHGZLWKDFDQFHUFDXVLQJ&XVKLQJ¶VV\QGURPH will need 
an individualised discussion of the risks vs. benefits of cancer therapy during 
COVID-19, either with surgery and/or medical approaches6. 
x Surgery should be considered only in patients who cannot be controlled with 
medical therapy, or those requiring biopsy or resection because of possible 
cancer. 
x When there is lower SARS-CoV-2 viral prevalence and when appropriate 
institutional measures have been implemented to provide safety for patients, 
elective surgical transsphenoidal surgery and other surgical procedures can be 
reconsidered.  It is implicit that the appropriate diagnostic procedures will be 
needed prior to these. 
 
Medical therapy 
The following principles are recommended: 
x Co-morbidities should be treated as for standard of care2.  
x Avoid initiation of ACE inhibitors or AT1 receptor blockers for treatment of 
hypertension until their influence on susceptibility to SARS-CoV-19 infection is 
clarified7, but it is not suggested to stop these in those patients already on 
treatment with satisfactory control. 
x For most patients, steroidogenesis inhibitors will be the mainstay of treatment 
VLQFHWKH\WUHDWDOOW\SHVRI&XVKLQJ¶VV\QGURPH 
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x A glucocorticoid receptor (GR) antagonist also may be used but is difficult to 
titrate and is not universally available8, and is only indicated for treatment of 
K\SHUWHQVLRQDQGGLDEHWHVPHOOLWXVLQ&XVKLQJ¶VV\QGURPH 
x Patients with severe &XVKLQJ¶V V\QGURPH should receive prophylaxis for 
Pneumocystis jivoreci with trimethoprim/sulfamethoxazole2.  In patients with 
cough, fever and respiratory distress, differentiation should be made between 
COVID-19 infection and other pulmonary infections such as Pneumocystis 
jivoreci, that may share similar CT features, to ensure appropriate treatment. 
x It is recommended that treatment with low molecular weight heparin be given 
until definitive treatment has been achieved, especially in patients with 
moderate to severe disease2. 
x Dopamine agonists and somatostatin analogues do not reliably lower plasma 
ACTH and serum cortisol in all patients and are not recommended as mono-
therapy in a patient needing urgent biochemical control. 
x Regular telephone (or, if possible, video) consultations are recommended to 
assess response to treatment, including symptoms of hypoadrenalism, and 
self-reported weight, BP and capillary glucose. 
 
Monitoring and initiation of medical therapy 
Principles 
x Where possible, it is suggested that the majority of patients, especially those 
with more severe clinical features or any features that suggest cyclical disease 
DUH FRQVLGHUHG IRU D µEORFN DQG UHSODFH¶ DSSURDFK ZKHQ VWHURLGRJHQHVLV
inhibitors are used (Figure 2).  Once established, this approach limits the need 
for biochemical monitoring and reduces the risk of adrenal insufficiency.  The 
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VXJJHVWHGUHJLPHLVIRUDIXOO µEORFNDQGUHSODFH¶EXWWKLVPD\EHPRGLILHGLQ
FROODERUDWLRQZLWKH[SHUWVLQ&XVKLQJ¶VWRDSDUWLDO µEORFN¶UHJLPHZLWKUHJXODU
telephone monitoring of symptoms. 
x Urinary free cortisol (UFC) measurement allows remote monitoring for all 
patients (collect urine for 24 hours, measure volume, post aliquot to lab) except 
for those on GR antagonists and those on block and replace regimes that use 
hydrocortisone.  UFC measurement cannot be used to identify overtreatment 
on a dose titration regime. If using metyrapone, a mass spectrometry assay is 
needed to measure UFC as metyrapone inhibits CYP11B1, resulting in 
accumulation of tetrahydro-11-deoxycortisol, which will cross react with many 
cortisol immunoassays. 
x If dose titration used, pre-dose serum cortisol values also may be used to 
estimate control and can be done at a local lab for patients remote from the 
centre. Assuming a relative lack of diurnal variation, morning cortisol goal 
values are 250 ± 330 nmol/L (9 ± 12 mcg/dL), but higher levels (250-500 
nmol/L) may be acceptable in the short to medium term if regular monitoring is 
challenging in order to avoid hypoadrenalism. When using metyrapone the 
immunoassay must not cross react with 11-deoxycortisol, and where available, 
mass spectrometry assays are recommended.  
 
Patients on existing long-term treatment 
x If the recent clinical state, drug dose and biochemical monitoring for cortisol 
excess are stable and controlled, patients should be maintained on their current 
regimen.  
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x 3DWLHQWVRQDQ\IRUPRIWUHDWPHQWIRU&XVKLQJ¶VV\QGURPHFDQEHFRQVLGHUHG
for switching to a block and replace regime (see below) if that will allow either 
better control or ease of monitoring with fewer patient visits. 
x Consideration should be given to extending the intervals between biochemical 
PRQLWRULQJLQOLQHZLWKµSULQFLSOHVRIFDUH¶DERYe.  
x Patients should have access to stress doses of glucocorticoid tablets (e.g. 20 
mg hydrocortisone four times daily for up to two weeks), and preferably an 
emergency injection kit for intra-muscular injection of 100 mg hydrocortisone in 
case of intercurrent infection or trauma (see 
https://www.endocrinology.org/clinical-practice/covid-19-resources-for-
managing-endocrine-conditions/) 
x 3DWLHQWVQHHGHGXFDWLRQDERXWµVLFNGD\UXOHV¶DQGWRWDNHH[WUDJOXFRFRUWLFRLG
if unwell, and to liaise with their treating physician/nurse specialist as needed 
via a designated contact telephone/email or other means. It is best for patients 
to have written instructions for stress dose adjustments and other emergencies.  
 
Patients needing initiation of treatment 
x Country-specific availability will determine which agent can be used.  Patients 
on ketoconazole, however, should have liver function monitored every month 
(deviating from EMA guidance for weekly testing) for the first three months at 
the start of treatment or following a dose increase as this has been found to be 
safe9. Ketoconazole also has a slower onset of action than metyrapone, and 
has a greater number of drug-drug interactions because of inhibition of 
CYP3A4. For these reasons, where available, metyrapone is suggested as 
being preferable.  
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x Ketoconazole needs an acid gastric environment to be absorbed (avoid proton 
pump inhibitors). 
x Hypokalaemia may be exacerbated by metyrapone and GR antagonists; this 
should be anticipated and treated with potassium supplements or 
mineralocorticoid antagonists.   
x Some biochemical monitoring will likely be required for any of these agents.   
x Combination treatment with ketoconazole and metyrapone can be considered 
from the outset in severe cases10, and requires monitoring of liver biochemistry 
as above.  
x ,IDSDWLHQWRQPHGLFDOWUHDWPHQWIRU&XVKLQJ¶Vsyndrome is infected by SARS-
C0V-2 it is recommended that stress doses of glucocorticoid are given. 
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Figure legends 
 
Figure 1 
 
Suggested DOJRULWKPIRULQYHVWLJDWLRQDQGPDQDJHPHQWRIVXVSHFWHG&XVKLQJ¶V
syndrome during COVID-19 pandemic.  
ONDST: overnight dexamethasone suppression test; UFC: urinary free cortisol; ACC: 
adrenocortical cancer. 1The higher the UFC or post-dexamethasone serum cortisol 
WKH JUHDWHU WKH FRQILGHQFH WKDW WKH SDWLHQW KDV &XVKLQJ¶V V\QGURPH 2MRI or CT 
pituitary if clear visual field defects to identify sight-threatening macroadenoma ± CT 
head with coronal reconstructions can be included in the body CT to minimise need 
for extra imaging 
 
Figure 2 
 
0HGLFDOPDQDJHPHQWE\µ%ORFNDQG5HSODFH¶.  
These recommendations for block and replace regime DUHµH[SHUWDGYLFH¶UDWKHUWKDQ
being evidence-based. Telephone consultations should evaluate symptomatology, 
weight, BP and capillary blood glucose to assist judging the effectiveness of the 
replacement glucocorticoid dose. 3DWLHQWV VKRXOG EH LQVWUXFWHG WR IROORZ µVLFN GD\
UXOHV¶IRUJOXFRFRUWLFRLGUHSODFHPHQWVHHWH[W 
Note: when using metyrapone any assay that has cross-reactivity with 11-
deoxycortisol will read falsely high ± where possible LC-MS/MS assays are 
recommended; * doses may be increased further if needed, and ketoconazole and 
metyrapone may be used in combination; with monitoring it may also be possible to 
reduce the dose whilst maintaining blockade - FROODERUDWLRQZLWKH[SHUWLQ&XVKLQJ¶V
is recommended. 
 
 
